In this free webinar, learn about the advantages of leveraging EPQT and AI-powered data quality in early phase QT assessment. The featured speakers will share considerations for determining whether early phase QT data may support regulatory waiver of a stand-alone QT study. Attendees will learn how automatic, AI-enabled ECG quality assessments can provide timely feedback on the overall quality of the data and can help reduce the risk of missing or inaccurate data that is essential for obtaining a QT waiver.
TORONTO, Dec. 16, 2025 /PRNewswire/ — Early and accurate Phase I data is crucial to maintaining safety and determining the viability of new drug entities. Cardiac safety assessments, particularly those focused on the QT interval, play a key role in assessing potential toxicity and guiding portfolio decisions. Therefore, accurately evaluating cardiac safety earlier in the development process may save time, resources and costly future studies.
Traditionally, QT assessments have been conducted in later stages of clinical development in Thorough QT (TQT) studies. However, a more proactive approach is available: early phase QT assessments performed in healthy volunteers during Phase I studies. However, relying on the site investigator’s interpretation of 12-lead ECGs typically does not provide the precision needed to detect QT interval changes at the threshold required by health authorities in support of a QT waiver.
By combining high-precision, early-phase QT assessments from the early precision QT (EQPT) methodology with AI-enabled ECG quality checks, drug developers can obtain actionable safety data that informs critical decisions early in the development process. This proactive assessment of cardiac safety risks can help mitigate potential toxicities before they escalate, improving the likelihood of successful drug development and reducing the risk of late-stage failures.
In many cases, early-phase findings can support a waiver of a dedicated TQT study, reducing the need for a costly and time-consuming trial later in development.
Register now to gain a clearer understanding of EPQT to ensure data quality, create efficiencies and potentially qualify for a TQT waiver.
Join Vic Patel (Moderator), MD, PhD, Vice President & Chief Medical Officer, Cardiology, Clario; Dr. Borje Darpo, MD, PhD, Chief Scientific Officer, Cardiac Safety, Clario; and Jean-Philippe Couderc, PhD, MBA, Professor of Medicine and Computer/Electrical Engineering, University of Rochester, for the live webinar on Wednesday, January 14, 2026, at 11am EST (5pm CET/EU-Central).
For more information, or to register for this event, visit Improve Effectiveness of Cardiac Assessments in Early Phase Trials with Early Precision QT and AI-powered Data Quality Checks.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/improve-effectiveness-of-cardiac-assessments-in-early-phase-trials-with-early-precision-qt-and-ai-powered-data-quality-checks-upcoming-webinar-hosted-by-xtalks-302643866.html
SOURCE Xtalks
